



Advanced Research in Lysosomal Storage Disorders

Guest Editors:

Dr. Francisco J. del Castillo

1. Servicio de Genética, Hospital
Universitario Ramón y Cajal -
IRYCIS, Madrid, Spain

2. Unit 728, Centro de
Investigación Biomédica en Red
de Enfermedades Raras
(CIBERER), Madrid, Spain

Prof. Dr. Enrique J. Calderón

Departamento de Medicina,
Instituto de Biomedicina de
Sevilla, CIBERESP, Hospital
Universitario Virgen del Rocío,
Facultad de Medicina,
Universidad de Sevilla, Sevilla,
Spain

Message from the Guest Editors

Lysosomal diseases (LDs) are a group of about 70 hereditary metabolic disorders caused by the inactivation of one of the genes encoding components of lysosomal machinery. LDs are rare diseases (combined incidence of about 1:5500) with mainly recessive inheritance. This Special Issue of *Biomedicines* will showcase novel developments in the field, presenting the state of the art on the screening, diagnosis, pathophysiology, and treatment of lysosomal diseases from all points of view (clinical, biochemical, genomic, and biomarkers) and will highlight questions that need to be addressed in the field.

Deadline for manuscript
submissions:

closed (30 April 2024)





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)